2. Search Result
Search Result
Results for "

transient middle cerebral artery occlusion

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17355
    Pramipexole dihydrochloride
    Maximum Cited Publications
    13 Publications Verification

    		 Dopamine Receptor Neurological Disease
    Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole dihydrochloride
  • HY-B0410
    Pramipexole
    Maximum Cited Publications
    13 Publications Verification

    		 Dopamine Receptor Neurological Disease
    Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole
  • HY-121833
    Gambogic amide

    		Trk Receptor Akt ERK Neurological Disease Cancer
    Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke .
    Gambogic amide
  • HY-B0410A
    Pramipexole dihydrochloride hydrate
    Maximum Cited Publications
    13 Publications Verification

    		 Dopamine Receptor Neurological Disease
    Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole dihydrochloride hydrate
  • HY-178393
    TRPM2-IN-2

    		TRP Channel Neurological Disease Metabolic Disease
    TRPM2-IN-2 is a potent and selective TRPM2 inhibitor (IC50 = 0.66 μM) with minimal activity against TRPM8 and TRPV1 (IC50 >10 μM). TRPM2-IN-2 exhibits robust neuroprotective effects in both in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model and in vivo transient middle cerebral artery occlusion (tMCAO) mouse model. TRPM2-IN-2 can be used for ischemic stroke research .
    TRPM2-IN-2
  • HY-168501
    Neuroprotective agent 6

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    Neuroprotective Agent 6 (Compound Y12) is a neuroprotective agent with antioxidant activity and capabilities in DPPH, ABTS radical scavenging. Neuroprotective Agent 6 demonstrates superior neuroprotective effects in both cellular models induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and animal models induced by transient middle cerebral artery occlusion (tMCAO). Additionally, Neuroprotective Agent 6 exhibits significant metal chelating activity towards Cu 2+ .
    Neuroprotective agent 6
  • HY-175027
    RIPK1-IN-33

    		RIP kinase Ferroptosis Neurological Disease
    RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC50 of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC50 = 123.3 μM), and anti-lipid peroxidation effects (IC50 = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke .
    RIPK1-IN-33
  • HY-B0410AR
    Pramipexole dihydrochloride hydrate (Standard)

    		Reference Standards Dopamine Receptor Neurological Disease
    Pramipexole (dihydrochloride hydrate) (Standard) is the analytical standard of Pramipexole (dihydrochloride hydrate). This product is intended for research and analytical applications. Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole dihydrochloride hydrate (Standard)
  • HY-B0410R
    Pramipexole (Standard)

    		Reference Standards Dopamine Receptor Neurological Disease
    Pramipexole (Standard) is the analytical standard of Pramipexole. This product is intended for research and analytical applications. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole (Standard)
  • HY-P11848
    P3LC7LC-P

    		iGluR Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease
    P3LC7LC-P is a blood-brain barrier-permeable BRAG2 ligand with a KD of 6.14 μM. P3LC7LC-P binds to BRAG2, thereby disrupting its interaction with the GluA2 subunit of the AMPA receptor and inhibiting glutamate-induced GluA2 endocytosis. P3LC7LC-P exerts neuroprotective effects in oxygen-glucose deprivation-induced and glutamate-induced neurotoxicity models, reduces ROS accumulation and inhibits apoptosis, and reduces cerebral infarct size in a rat model of transient middle cerebral artery occlusion. P3LC7LC-P can be used for the research of ischemic stroke .
    P3LC7LC-P
  • HY-181124
    Idebenone-SS-20

    Idebenone-2S-FrFK-NH2

    		 Drug Derivative Reactive Oxygen Species (ROS) Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Idebenone-SS-20 (Idebenone-2S-FrFK-NH2) is a Idebenone (HY-N0303) derivative conjugated to the mitochondria-targeting peptide SS-20. Idebenone-SS-20 shows neuroprotective and anti-inflammatory effects. Idebenone-SS-20 can preserve mitochondrial membrane potential, enhance ATP production, reduce ROS accumulation, maintain mitochondrial morphology and elevate NAD+/NADH ratio. Idebenone-SS-20 confers robust neuroprotection in a murine model of transient middle cerebral artery occlusion. Idebenone-SS-20 can be used for the research of cerebral .
    Idebenone-SS-20
  • HY-17355R
    Pramipexole dihydrochloride (Standard)

    		Dopamine Receptor Reference Standards Neurological Disease
    Pramipexole (dihydrochloride) (Standard) is the analytical standard of Pramipexole (dihydrochloride). This product is intended for research and analytical applications. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .
    Pramipexole dihydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: